Neurocrine Biosciences, Inc.

With more than three decades of experience, the company has built a diverse portfolio of FDA-approved treatments including medications for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis, and uterine fibroids.

The company maintains a robust pipeline of multiple compounds in mid- to late-phase clinical development across its core therapeutic areas.

Neurocrine applies unique insights into neuroscience and the interconnections between brain and body systems to treat complex conditions and relieve suffering for people with great needs.